Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

998 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
M-CSF as a therapeutic target in BRAFV600E melanoma resistant to BRAF inhibitors.
Barceló C, Sisó P, de la Rosa I, Megino-Luque C, Navaridas R, Maiques O, Urdanibia I, Eritja N, Soria X, Potrony M, Calbet-Llopart N, Puig S, Matías-Guiu X, Martí RM, Macià A. Barceló C, et al. Among authors: puig s. Br J Cancer. 2022 Oct;127(6):1142-1152. doi: 10.1038/s41416-022-01886-4. Epub 2022 Jun 20. Br J Cancer. 2022. PMID: 35725813 Free PMC article.
Temozolomide as prophylaxis for melanoma brain metastases.
Conill C, González-Cao M, Jorcano S, Puig S, Malvehy J, Martí R, Castel T. Conill C, et al. Among authors: puig s. Melanoma Res. 2004 Feb;14(1):73-4. doi: 10.1097/00008390-200402000-00012. Melanoma Res. 2004. PMID: 15091198 Clinical Trial. No abstract available.
Seborrheic keratosislike melanoma with folliculotropism.
Carrera C, Segura S, Palou J, Puig S, Segura J, Martí RM, Malvehy J. Carrera C, et al. Among authors: puig s. Arch Dermatol. 2007 Mar;143(3):373-6. doi: 10.1001/archderm.143.3.373. Arch Dermatol. 2007. PMID: 17372102
Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.
Yeramian A, Sorolla A, Velasco A, Santacana M, Dolcet X, Valls J, Abal L, Moreno S, Egido R, Casanova JM, Puig S, Vilella R, Llombart-Cussac A, Matias-Guiu X, Martí RM. Yeramian A, et al. Among authors: puig s. Int J Cancer. 2012 Feb 15;130(4):967-78. doi: 10.1002/ijc.26096. Epub 2011 Jun 18. Int J Cancer. 2012. PMID: 21445974
Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
Potrony M, Puig-Butillé JA, Aguilera P, Badenas C, Carrera C, Malvehy J, Puig S. Potrony M, et al. Among authors: puig s, puig butille ja. J Am Acad Dermatol. 2014 Nov;71(5):888-95. doi: 10.1016/j.jaad.2014.06.036. Epub 2014 Jul 24. J Am Acad Dermatol. 2014. PMID: 25064638 Free PMC article.
TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Griewank KG, Murali R, Puig-Butille JA, Schilling B, Livingstone E, Potrony M, Carrera C, Schimming T, Möller I, Schwamborn M, Sucker A, Hillen U, Badenas C, Malvehy J, Zimmer L, Scherag A, Puig S, Schadendorf D. Griewank KG, et al. Among authors: puig s, puig butille ja. J Natl Cancer Inst. 2014 Sep 13;106(9):dju246. doi: 10.1093/jnci/dju246. Print 2014 Sep. J Natl Cancer Inst. 2014. PMID: 25217772 Free PMC article.
The MC1R melanoma risk variant p.R160W is associated with Parkinson disease.
Tell-Marti G, Puig-Butille JA, Potrony M, Badenas C, Milà M, Malvehy J, Martí MJ, Ezquerra M, Fernández-Santiago R, Puig S. Tell-Marti G, et al. Among authors: puig s, puig butille ja. Ann Neurol. 2015 May;77(5):889-94. doi: 10.1002/ana.24373. Epub 2015 Mar 13. Ann Neurol. 2015. PMID: 25631192
998 results